Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

West Pharmaceutical Services (WST)

NYSE: WST · Health Care Supplies · Exton, PA

Our rating: Neutral

Neutral reaffirmed at $412.62, moderate conviction, October 30, 2026.

Breaks if: The Neutral call turns Cautious if reported organic revenue growth falls below 4% for two consecutive quarters — evidence the injectable-drug tailwind is decelerating faster than the 60x multiple can tolerate. It turns Positive if organic revenue growth reaches or exceeds 10% for two consecutive quarters, which would begin to close the visible gap between the current growth rate and the rate the implied multiple demands.

Key figures

Market value$27.2B
Revenue, last 12 months$3.4B
Net income, last 12 months$639M
Free cash flow, last 12 months$453M
Price to earnings42.6×
Free cash flow yield1.7%
Dividend yield0.3%
Operating margin23.0%
Return on equity21.2%
Beta to the S&P 5000.57
Volatility, annualized44.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$875M8.7%$3.02$150M
June 30, 2026$872M13.8%$2.15$81M
March 31, 2026$845M21.0%$1.92$47M
December 31, 2025$805M7.5%$1.82$175M
September 30, 2025$805M7.7%$1.92$134M
June 30, 2025$767M9.2%$1.82$102M
March 31, 2025$698M0.4%$1.23$58M
December 31, 2024$749M2.3%$1.78$85M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 51 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.